Log In
BCIQ
Print this Print this
 

TRO40303

  Manage Alerts
Collapse Summary General Information
Company Roche
DescriptionPeripheral benzodiazepine receptor (TSPO; PBR) ligand
Molecular Target Peripheral benzodiazepine receptor (TSPO) (PBR)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationIschemia / reperfusion injury
Indication DetailsTreat cardiac ischemia/reperfusion injury; Treat cardiac ischemia/reperfusion injury in acute myocardial infarction (AMI) patients
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$556.0M

$142.0M

$414.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/03/2015

$556.0M

$142.0M

$414.0M

Get a free BioCentury trial today